Matches in SemOpenAlex for { <https://semopenalex.org/work/W3204042287> ?p ?o ?g. }
- W3204042287 endingPage "4884" @default.
- W3204042287 startingPage "4884" @default.
- W3204042287 abstract "Prognostic or predictive biomarkers in HER2-positive early breast cancer (EBC) may inform treatment optimization. The ADAPT HER2-positive/hormone receptor-positive phase II trial (NCT01779206) demonstrated pathological complete response (pCR) rates of ~40% following de-escalated treatment with 12 weeks neoadjuvant ado-trastuzumab emtansine (T-DM1) ± endocrine therapy. In this exploratory analysis, we evaluated potential early predictors of response to neoadjuvant therapy. The effects of PIK3CA mutations and immune (CD8 and PD-L1) and apoptotic markers (BCL2 and MCL1) on pCR rates were assessed, along with intrinsic BC subtypes. Immune response and pCR were lower in PIK3CA-mutated tumors compared with wildtype. Increased BCL2 at baseline in all patients and at Cycle 2 in the T-DM1 arms was associated with lower pCR. In the T-DM1 arms only, the HER2-enriched subtype was associated with increased pCR rate (54% vs. 28%). These findings support further prospective pCR-driven de-escalation studies in patients with HER2-positive EBC." @default.
- W3204042287 created "2021-10-11" @default.
- W3204042287 creator A5013148496 @default.
- W3204042287 creator A5014363979 @default.
- W3204042287 creator A5022444628 @default.
- W3204042287 creator A5025009422 @default.
- W3204042287 creator A5027231412 @default.
- W3204042287 creator A5027450608 @default.
- W3204042287 creator A5031666050 @default.
- W3204042287 creator A5034232595 @default.
- W3204042287 creator A5034354946 @default.
- W3204042287 creator A5040331693 @default.
- W3204042287 creator A5040435806 @default.
- W3204042287 creator A5042456607 @default.
- W3204042287 creator A5044665296 @default.
- W3204042287 creator A5048307202 @default.
- W3204042287 creator A5053751196 @default.
- W3204042287 creator A5061507425 @default.
- W3204042287 creator A5061863743 @default.
- W3204042287 creator A5069170386 @default.
- W3204042287 creator A5081829270 @default.
- W3204042287 creator A5090984572 @default.
- W3204042287 date "2021-09-29" @default.
- W3204042287 modified "2023-10-02" @default.
- W3204042287 title "Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer" @default.
- W3204042287 cites W2006070721 @default.
- W3204042287 cites W2033173589 @default.
- W3204042287 cites W2075894019 @default.
- W3204042287 cites W2109916911 @default.
- W3204042287 cites W2112648444 @default.
- W3204042287 cites W2114149997 @default.
- W3204042287 cites W2118419063 @default.
- W3204042287 cites W2119878357 @default.
- W3204042287 cites W2120431466 @default.
- W3204042287 cites W2132619562 @default.
- W3204042287 cites W2138604360 @default.
- W3204042287 cites W2144442992 @default.
- W3204042287 cites W2147299492 @default.
- W3204042287 cites W2147415463 @default.
- W3204042287 cites W2159967578 @default.
- W3204042287 cites W2162982444 @default.
- W3204042287 cites W2165139474 @default.
- W3204042287 cites W2170181527 @default.
- W3204042287 cites W2173303337 @default.
- W3204042287 cites W2178732328 @default.
- W3204042287 cites W2286693725 @default.
- W3204042287 cites W2340698646 @default.
- W3204042287 cites W2352525452 @default.
- W3204042287 cites W2407664560 @default.
- W3204042287 cites W2470412971 @default.
- W3204042287 cites W2506902454 @default.
- W3204042287 cites W2528031397 @default.
- W3204042287 cites W2541170168 @default.
- W3204042287 cites W2591481727 @default.
- W3204042287 cites W2764265362 @default.
- W3204042287 cites W2768649895 @default.
- W3204042287 cites W2771978163 @default.
- W3204042287 cites W2792379967 @default.
- W3204042287 cites W2807256946 @default.
- W3204042287 cites W2902218997 @default.
- W3204042287 cites W2910609377 @default.
- W3204042287 cites W2914757005 @default.
- W3204042287 cites W2923651250 @default.
- W3204042287 cites W2923800831 @default.
- W3204042287 cites W2930274452 @default.
- W3204042287 cites W2942862617 @default.
- W3204042287 cites W2946968461 @default.
- W3204042287 cites W2947102480 @default.
- W3204042287 cites W2947111998 @default.
- W3204042287 cites W2947469974 @default.
- W3204042287 cites W2947774574 @default.
- W3204042287 cites W2948405934 @default.
- W3204042287 cites W2961718842 @default.
- W3204042287 cites W2977267327 @default.
- W3204042287 cites W3013441775 @default.
- W3204042287 cites W3088588360 @default.
- W3204042287 cites W4254815115 @default.
- W3204042287 doi "https://doi.org/10.3390/cancers13194884" @default.
- W3204042287 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8508505" @default.
- W3204042287 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34638369" @default.
- W3204042287 hasPublicationYear "2021" @default.
- W3204042287 type Work @default.
- W3204042287 sameAs 3204042287 @default.
- W3204042287 citedByCount "11" @default.
- W3204042287 countsByYear W32040422872022 @default.
- W3204042287 countsByYear W32040422872023 @default.
- W3204042287 crossrefType "journal-article" @default.
- W3204042287 hasAuthorship W3204042287A5013148496 @default.
- W3204042287 hasAuthorship W3204042287A5014363979 @default.
- W3204042287 hasAuthorship W3204042287A5022444628 @default.
- W3204042287 hasAuthorship W3204042287A5025009422 @default.
- W3204042287 hasAuthorship W3204042287A5027231412 @default.
- W3204042287 hasAuthorship W3204042287A5027450608 @default.
- W3204042287 hasAuthorship W3204042287A5031666050 @default.
- W3204042287 hasAuthorship W3204042287A5034232595 @default.
- W3204042287 hasAuthorship W3204042287A5034354946 @default.
- W3204042287 hasAuthorship W3204042287A5040331693 @default.
- W3204042287 hasAuthorship W3204042287A5040435806 @default.